Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers

Theranostics

Volumn 5, Issue 3, 2015, Pages 267-276

  Li, Qing Kay ^a   Chen, Li ^a   Ao, Ming Hui ^a   Chiu, Joyce Hanching ^a   Zhang, Zhen ^a   Zhang, Hui ^a   Chan, Daniel W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Fucosylated glycoprotein; Multiplex immunoassay; Prostate cancer; Prostate specific antigen; TIMP1

Indexed keywords

BIOLOGICAL MARKER; FUCOSYLATED PROSTATE SPECIFIC ANTIGEN; GLYCOPROTEIN; LECTIN; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FUCOSYLATION; GLEASON SCORE; HUMAN; IMMUNOASSAY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; TUMOR DIFFERENTIATION; BLOOD; CHEMISTRY; EVALUATION STUDY; GLYCOSYLATION; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; SERUM; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; GLYCOSYLATION; HUMANS; IMMUNOASSAY; KALLIKREINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE; SERUM; SEVERITY OF ILLNESS INDEX; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84924283376     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10349     Document Type: Article

References (38)

1. Siegel R, Ma J, Zhou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. J Clin Oncol. 2012;30:2768-75.
3. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, Walsh PC. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin. Chem. 1987;33:1916-20.
4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-28.
5. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104:125-32.
6. Sartori DA, Chan DW. Biomarkers in prostate cancer: what's new? Curr Opin Oncol. 2014;26:259-64.
7. [Internet] US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force recommendation statement. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/pro statefinalrs.htm
8. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012;4(127):127rv3.
9. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228-42.
10. Gulati R, Gore JL, Etzioni R. Comparative effectiveness of alternative prostate- specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med. 2013;158:145-53.
11. Tradonsky A, Rubin T, Beck R, Ring B, Seitz R, Mair S. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012;137:918-30.
12. Nogueira L, Corradi R, Eastham JA. Other biomarkers for detecting prostate cancer. BJU Int. 2010;105:166-9.
13. Martin SK, Vaughan TB, Atkinson T, Zhu H, Kyprianou N. Emerging biomarkers of prostate cancer. Oncol Rep. 2012;28:409-17.
14. Oon SF, Fanning DM, Fan Y, et al. The identification and internal validation of a preoperative serum biomarker panel to determine extracapsular extension in patients with prostate cancer. Prostate. 2012;72:1523-31.
15. Gilgunn S, Conroy PJ, Saldova R, Rudd PM, O'Kennedy RJ. Aberrant PSA glycosylation. A sweet predictor of prostate cancer. Nat Rev Urol. 2013;10:99-107.
16. Helenius A., Aebi M. Intracellular functions of N-linked glycans. Science 2001;291:2364-9.
17. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001;291:2370-6.
18. Drake PM, Cho W, Li B, et al. Sweetening the pot: adding glycosylation to the biomarker discovery equation. Clin. Chem. 2010;56:223-36.
19. Tian Y, Zhang H. Characterization of disease-associated N-linked glycoproteins. Proteomics 2013;13:504-11.
20. Dube DH, Bertozzi CR. Glycans in cancer and inflammation--potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4:477-88.
21. Meany DL, Chan DW. Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics. 2011;8:7.
22. Taketa K, Endo Y, Sekiya C, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993;53:5419-23.
23. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 1994;121:124-32.
24. Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen: a review of the literature. Hum Reprod. 1989;4:1-12.
25. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15-9.
26. Gorelik E, Galili U, Raz A. On the role of cell surface carbohydrates and their binding proteins (lectins) in tumor metastasis. Cancer Metastasis Rev. 2001;20:245-77.
27. Li D, Chiu H, Chen J, Zhang H, Chan DW. Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. Clin Chem. 2013;59:315-24.
28. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 1974;111:58-64.
29. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent- update 2013. Eur Urol. 2014;65:124-37.
30. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095-101.
31. Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. J Urol. 2005;173:73-8.
32. Li Y, Tao SC, Bova GS, et al. Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. Anal Chem. 2011;83:8509-16.
33. Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res. 2009;8:613-9.
34. Fukushima K, Satoh T, Baba S, Yamashita K. alpha1,2-Fucosylated and beta- N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology. 2010;20:452-60.
35. Saldova R, Fan Y, Fitzpatrick JM, Watson RW, Rudd PM. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2011;21:195-205.
36. Tabares G, Radcliffe CM, Barrabes S, et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology. 2006;16:132-45.
37. Kyselova Z, Mechref Y, Al Bataineh MM, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res 2007;6:1822-32.
38. Wang XC, Chen J, Li QK, et al. Overexpression of alpha (1,6) fucosyltransferase associated with aggressive prostate cancer. Glycobiology. 2014;24:935-44.